A tetravalent dengue nanoparticle stimulates antibody production in mice |
| |
Authors: | Elisangela F Silva Mariana Orsi ?ngela L Andrade Rosana Z Domingues Breno M Silva Helena RC de Araújo Paulo FP Pimenta Michael S Diamond Eliseu SO Rocha Erna G Kroon Luiz CC Malaquias Luiz FL Coelho |
| |
Affiliation: | 1. Institute of Biomedical Science, Federal University of Alfenas, Minas Gerais, Brazil 2. Department of Chemistry, Federal University of Ouro Preto, Ouro Preto, Minas Gerais, Brazil 3. Department of Chemistry, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil 4. Department of Biological Sciences, Federal University of Ouro Preto, Ouro Preto, Minas Gerais, Brazil 5. Laboratory of Medical Entomology, Instituto Ren?? Rachou, Funda??o Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil 6. Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA 7. Virus Laboratory, Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
|
| |
Abstract: | Background Dengue is a major public health problem worldwide, especially in the tropical and subtropical regions of the world. Infection with a single Dengue virus (DENV) serotype causes a mild, self-limiting febrile illness called dengue fever. However, a subset of patients experiencing secondary infection with a different serotype progresses to the severe form of the disease, dengue hemorrhagic fever/dengue shock syndrome. Currently, there are no licensed vaccines or antiviral drugs to prevent or treat dengue infections. Biodegradable nanoparticles coated with proteins represent a promising method for in vivo delivery of vaccines. Findings Here, we used a murine model to evaluate the IgG production after administration of inactivated DENV corresponding to all four serotypes adsorbed to bovine serum albumin nanoparticles. This formulation induced a production of anti-DENV IgG antibodies (p < 0.001). However, plaque reduction neutralization assays with the four DENV serotypes revealed that these antibodies have no neutralizing activity in the dilutions tested. Conclusions Our results show that while the nanoparticle system induces humoral responses against DENV, further investigation with different DENV antigens will be required to improve immunogenicity, epitope specicity, and functional activity to make this platform a viable option for DENV vaccines. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|